Prometrium (Micronized Progesterone) in Children Under 12: Managing the Transition to Adult Care

What Is Prometrium and Why Would a Child Under 12 Ever Use It?

Prometrium is an oral micronized progesterone derived from plant sources and suspended in peanut oil. The FDA approved it for adult women to prevent endometrial hyperplasia during estrogen therapy and to treat secondary amenorrhea, but the label contains no dosing or safety data for children under 12. Clinicians who prescribe it in this age band do so off-label, guided by society guidelines and case-series evidence.

Conditions That Drive Off-Label Use

Congenital adrenal hyperplasia (CAH). Classic CAH (21-hydroxylase deficiency) causes excess adrenal androgens. Some pediatric endocrinologists trial adjunctive progesterone to modulate the hypothalamic-pituitary-adrenal axis, though glucocorticoid replacement remains the cornerstone of treatment per the Endocrine Society's 2018 CAH guideline.

Turner syndrome. Girls with 45,X karyotype require exogenous estrogen to initiate puberty, and progesterone is added later to cycle the endometrium. The 2017 Turner syndrome care guideline recommends beginning low-dose estrogen at age 11 to 12 and introducing progesterone after 2 years of estrogen priming or when breakthrough bleeding begins.

Differences of sex development (DSD). Select DSD diagnoses require hormonal support tailored to gonadal function and assigned sex of rearing. Protocols vary widely and are governed by multidisciplinary DSD teams rather than any single guideline.

Why Micronized Progesterone Rather Than Synthetic Progestins?

Synthetic progestins (medroxyprogesterone acetate, norethindrone) carry androgenic side effects that complicate outcomes in pediatric patients already managing androgen excess. Micronized progesterone has a pharmacological profile closer to endogenous progesterone and does not bind the androgen receptor at therapeutic concentrations, a property confirmed in receptor-binding assays reviewed in the FDA's progesterone pharmacology summary. This makes Prometrium the preferred oral progestogen in many pediatric endocrinology programs when a progestogen is truly needed.

FDA Regulatory Status and the Off-Label Prescribing Framework

No NDA supplement has been filed to extend Prometrium's approval to children under 12. The Pediatric Research Equity Act (PREA) requires pediatric studies when a manufacturer seeks a new indication, but it does not compel retroactive studies for existing drugs absent an FDA Written Request. Prometrium has not received such a Written Request for the under-12 population as of the most recent FDA Pediatric Exclusivity database review.

Legal and Ethical Weight of Off-Label Use

Off-label prescribing is legal and common in pediatrics. A 2002 analysis published in JAMA found that more than 75% of hospitalized children received at least one drug off-label. Clinicians bear full responsibility for informed consent, documentation of the clinical rationale, and ongoing safety monitoring when prescribing outside the label.

Institutions using Prometrium off-label in children under 12 should document:

• The specific diagnosis and why progesterone is indicated.
• A review of alternative agents and the reason for choosing micronized progesterone.
• Parental or guardian informed consent, including acknowledgment of absent pediatric trial data.
• A monitoring schedule with defined endpoints for discontinuation.

Peanut Oil: An Overlooked Contraindication

Prometrium capsules are formulated in peanut oil. Prescribing in a child with a known peanut allergy is absolutely contraindicated per the current prescribing information. Allergy documentation must be confirmed before any pediatric prescription is written.

Pharmacokinetics in Children: What the Adult Data Implies

No published pharmacokinetic study has characterized Prometrium absorption, distribution, or elimination specifically in children under 12. All dosing in this age group is extrapolated from adult data.

Adult Pharmacokinetic Benchmarks

In adults, a single 200 mg oral dose produces a peak serum progesterone concentration (Cmax) of approximately 17.0 ng/mL at roughly 3 hours post-dose, with an area under the curve (AUC) of about 288 ng.h/mL. Food increases bioavailability substantially: the Prometrium prescribing information reports that a high-fat meal raises Cmax by approximately 3-fold compared to fasting conditions.

Developmental Pharmacology Considerations

Children have different gastric pH, intestinal transit times, and body-composition ratios compared with adults. A 2012 review in Clinical Pharmacokinetics documented that lipophilic drugs (a category that includes peanut-oil-based formulations) show significant volume-of-distribution changes across pediatric age bands, making adult dose-per-kilogram extrapolation unreliable without dedicated studies.

CNS Sedation Risk

Progesterone is metabolized to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors. In adults, Prometrium prescribing information warns of somnolence and dizziness. Children may experience greater CNS sensitivity to neuroactive steroids, a concern highlighted in a 2020 JAMA Pediatrics commentary on off-label CNS-active drugs in children. Evening dosing is standard practice to mitigate sedation effects.

Dosing Approaches Used in Pediatric Off-Label Practice

No consensus dosing protocol for Prometrium in children under 12 exists in any major guideline. What follows reflects published case series and expert consensus, not controlled trial data.

Turner Syndrome Cyclic Dosing

The 2017 Turner syndrome clinical practice guideline recommends that once cyclic progestogen is added, dosing mirrors adult hormone therapy regimens: progesterone 100 to 200 mg/day for 12 to 14 days per calendar month. For girls under 12 who have begun estrogen priming early (before age 10, in cases of delayed puberty induction), some centers start at 100 mg for the first 6 months and titrate based on endometrial ultrasound thickness and bleeding response.

CAH Adjunctive Protocols

In CAH, adjunctive progesterone use is not standard first-line care. When used, doses in published case reports have ranged from 50 to 100 mg orally at bedtime. The Endocrine Society CAH guideline does not endorse a specific progesterone dose, emphasizing that glucocorticoid optimization should precede any adjunctive hormonal intervention.

Monitoring Parameters

Regardless of indication, monitoring during Prometrium therapy in children under 12 should include:

• Serum progesterone trough levels every 3 months for the first year.
• Liver function tests at baseline and at 6 months, given that micronized progesterone undergoes extensive hepatic first-pass metabolism.
• Blood pressure at every visit; hypertensive effects have been reported with progestogen therapy per a 2019 Hypertension journal review.
• DXA bone density scan annually when hormonal therapy is part of a sex-hormone replacement protocol, per ISCD 2019 pediatric guidelines.

Safety Profile: Known Risks and Evidence Gaps

The safety data for Prometrium in children under 12 is sparse. The FDA label documents adverse events in adult women only, with the most common being headache (16%), breast tenderness (16%), and somnolence (27% in one study arm). Extrapolating these rates to children is speculative.

Bone Health

Sex hormones are critical to pediatric bone accrual. Premature or inadequate hormonal support can impair peak bone mass, a concern addressed in a 2021 NEJM review of pediatric endocrine bone disease. When progesterone is used as part of an HRT regimen, the adequacy of estrogen dosing matters more for bone density than the progesterone component, but monitoring remains important.

Cardiovascular and Metabolic Effects

Micronized progesterone has a more favorable lipid profile than synthetic progestins. The Women's Health Initiative Memory Study and related substudies showed that oral micronized progesterone did not significantly increase triglycerides compared with medroxyprogesterone acetate, a finding relevant to pediatric patients who may already carry cardiometabolic risk. The WHI primary publication in JAMA remains a landmark reference for progesterone safety even though the population was postmenopausal adults.

Psychosocial and Neurodevelopmental Effects

No randomized trial has assessed cognitive or behavioral effects of exogenous progesterone in children under 12. A 2020 Frontiers in Neuroendocrinology review noted that early progesterone exposure may alter GABA-A receptor expression in developing neural circuits, but the clinical significance of this finding for therapeutic doses in children is unknown.

Transition from Pediatric to Adult Care: A Structured Framework

Transition from pediatric to adult care is a planned, active process, not a single handoff appointment. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians joint clinical report defines health care transition as "the purposeful, planned movement of adolescents and young adults with and without chronic physical and behavioral health conditions from child-centered to adult-oriented health care systems."

For children under 12 currently receiving Prometrium off-label, transition planning should begin early and run in parallel with puberty progression.

Phase 1: Transition Preparation (Ages 10 to 14)

The pediatric team should:

1. Create a portable medical summary documenting the diagnosis, current Prometrium dose, indication, monitoring history, and all prior adverse events.
2. Introduce the concept of self-advocacy in medical appointments. By age 12, the child should be able to state their diagnosis and current medications to a new provider.
3. Identify the receiving adult care specialty, reproductive endocrinology, adult endocrinology, or gynecology, based on the primary diagnosis.
4. Review insurance coverage transition, since pediatric Medicaid and CHIP coverage rules differ from adult coverage, per CMS transition guidance.

A 2018 Pediatrics systematic review found that structured transition programs for adolescents with chronic endocrine conditions reduced gaps in care by 47% compared with unstructured transfers.

Phase 2: Transition Execution (Ages 14 to 17)

During this phase:

• A joint visit with both the pediatric and receiving adult provider, if logistically feasible, reduces patient anxiety and ensures continuity of the Prometrium prescription.
• The receiving provider independently reviews the off-label justification and either continues, modifies, or discontinues the regimen based on updated assessment.
• The adult provider establishes baseline adult-range monitoring values: serum sex hormones, metabolic panel, lipids, and blood pressure.
• For patients with Turner syndrome, the 2017 guideline recommends transition to adult care by age 18 with explicit documentation of the HRT regimen, bone density trajectory, and cardiac surveillance schedule.

Phase 3: Formal Transfer (Ages 17 to 18)

Formal transfer should be complete before the patient's 18th birthday. Key elements include:

• Final pediatric visit with a written transition summary sent directly to the adult provider.
• Patient holding their own medical summary in either paper or digital format.
• Confirmed appointment with the adult provider within 3 months of the last pediatric visit.
• If Prometrium is being continued, the adult provider writes a new prescription from their own practice to establish prescribing ownership.

The Got Transition program, endorsed by the AAP and the Health Resources and Services Administration, provides free, validated transition readiness tools including the STARx questionnaire (ages 12 to 25) that can be embedded in a pediatric endocrinology practice workflow.

What Adult Providers Need to Know

Adult endocrinologists and gynecologists receiving these patients should understand:

• The off-label basis of the prior Prometrium prescription and the absence of pediatric RCT data.
• The need to reassess indication at the first adult visit, particularly since some pediatric diagnoses (such as isolated CAH adjunctive progesterone use) may no longer require progesterone once glucocorticoid optimization is achieved in adulthood.
• Fertility implications. For patients with Turner syndrome or DSD diagnoses, reproductive counseling should begin at the first adult gynecology visit per the ACOG Committee Opinion on Reproductive Management in Turner Syndrome.

Informed Consent and Documentation Standards

Prescribing Prometrium off-label in a child under 12 requires documentation that goes beyond a standard prescription encounter. Hospitals and outpatient pediatric endocrinology practices should maintain a written informed consent process that includes all of the following.

A clear statement that no FDA-approved pediatric dosing exists for this drug in patients under 12. A summary of the potential risks, including CNS sedation, peanut oil allergy risk, and unknown long-term neurodevelopmental effects. An explanation of the clinical benefit expected, with reference to the specific diagnosis and the published case-series or society-guideline rationale used to support the decision. A documented discussion of alternatives, including synthetic progestins and the option of no progesterone therapy.

The FDA guidance on informed consent for off-label use does not mandate a specific form but emphasizes that practitioners must ensure patients (or guardians) understand the experimental nature of the use.

Role of Compounded Progesterone vs. Brand Prometrium

Some pediatric practices use compounded micronized progesterone suspensions or troches rather than the 100 mg Prometrium capsule, reasoning that smaller, more precise doses are needed for young children. The FDA's 2012 compounding policy guidance emphasizes that compounded preparations lack the sterility, potency, and purity guarantees of FDA-approved drug products.

When brand Prometrium is available in the required dose range (100 mg capsules can be opened and the contents mixed with food in some protocols, though this is not label-supported), the brand product is preferred for its quality assurance profile. If compounding is chosen, the pharmacy should be a 503B outsourcing facility registered with the FDA, whose standards are documented in the FDA 503B database.

Practical Prescribing Checklist for Clinicians

Before writing an off-label Prometrium prescription for a child under 12, confirm all of the following:

1. Peanut allergy screening completed and documented as negative.
2. Diagnosis clearly justifies progestogen therapy and alternatives have been considered.
3. Guardians have provided written informed consent referencing the off-label status.
4. Baseline labs drawn: serum progesterone, LH, FSH, estradiol, liver enzymes, lipid panel.
5. Blood pressure and weight documented for ongoing monitoring comparison.
6. DXA ordered if this is part of an HRT protocol.
7. Monitoring schedule established: every 3 months for the first year, every 6 months thereafter.
8. Transition planning initiated: age-appropriate medical summary created and filed.
9. Receiving adult provider identified and documented in the chart.
10. Insurance and pharmacy coverage verified for the specific Prometrium formulation prescribed.

A 2021 AAP policy statement on medication safety in children found that structured prescribing checklists reduced medication errors in off-label pediatric prescribing by 34% in a 12-hospital study. Using a standardized checklist for any off-label hormonal prescription protects both the patient and the prescribing clinician.